carnosine in Schizophrenia
Phase 3
Completed
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2019/02/017646
- Lead Sponsor
- Brio Bliss life science pvtltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1.Patients aged 18-40 years.
2.ICD -10 diagnosis of schizophrenia.
3.Willing to participate in the study
4.Education 9th std and above
5.Cognitive deficit of 15% on one domain of NIMHANS battery.
6.SANS total score > 60
Exclusion Criteria
1.Patients who are uncooperative due to the severity of the illness.
2.Existence of serious medical/neurological disorder, known allergic to L-carnosine.
3.Patients with mental retardation, H/O drug or alcohol dependence.
4.Women who were currently pregnant /breastfeeding.
5.Not consenting to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in negative symptoms and functioning in patients suffering from schizophrenia.Timepoint: 18 months
- Secondary Outcome Measures
Name Time Method improvement in cognitive symptomsTimepoint: 18 months